Company / Cash & Equivalents
Sotera Health Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$344.6M
FY2025
5-year range
$106.9M / $395.2M
FY2021-FY2025
Trend
+24.3%
vs FY2024
Sector context
#61 of 148
Health Care
What the data says
At $345M, Sotera Health's cash & equivalents ranks #61 of 148 in the Health Care sector. Cash & Equivalents returned to growth in FY2025 after 2 years of decline, reaching $345M.
Based on SEC 10-K filings.
$345M in FY2025 with a 5-year CAGR of +27.5%.
Improved from $296M to $345M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -4.5%
- 5-Year CAGR
- +27.5%
- 10-Year CAGR
- -
Sector benchmark
#61 of 148 in Health CareTop 41% of 148This company $344.6M Sector average $1.2B
▼
-71.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +27.5%, indicating consistent growth.
- In FY2025, cash & equivalents increased 24.3% year-over-year.
- Ranks #61 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $344.6M | +24.3% |
| FY2024 | $277.2M | -6.5% |
| FY2023 | $296.4M | -25.0% |
| FY2022 | $395.2M | +269.6% |
| FY2021 | $106.9M | +4.4% |
| FY2020 | $102.4M | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Feb 28, 2026